By Paula Arend Laier
(Reuters) – Hypera Pharma closed an agreement to acquire the developer and marketer of dermocosmetics Bioage, according to a company statement sent to the Brazilian Securities and Exchange Commission (CVM) on Thursday, which does not provide details on the amounts involved in the operation.
Bioage, which uses ‘cruelty-free’ and sustainable ingredients in the manufacture of its products, had revenues of 80 million reais in 2020. The company currently has a platform for direct customer service and 55 regional franchisees.
“The acquisition of Bioage is in line with the company’s strategic objective of strengthening its presence in the Brazilian skincare market through innovative products and brands,” said Hypera, adding that the transaction will also allow the group to enter the Brazilian aesthetic channel .
The post Hypera Pharma buys dermocosmetics company Bioage first appeared in ISTOÉ MONEY.